To ALL SWOG Cancer Research Network colleagues (not just my ASCO #GU23 network!): Michael Liss & I will be hosting a #microbiome symposium at the #SWOG Spring Mtg. Keynote from @BertrandRouty w talks from Laura Bukavina Nazli Dizman nadim_ajami. Want to hear concepts from #lungcancer, #melanoma, (1/2)

The legend and the man. Toni Choueiri, MD presents #Checkmate9ER biomarkers — gene expression profiling, #PDL1, #CD8, #MET associations w PFS outcomes. ASCO #GU23 OncoAlert

iPARPs in HRR negative population read our article!!! 👩🏻‍⚕️👨‍⚕️👩🏻‍⚕️ASCO #ASCOGU23 🇲🇽🇺🇸🇪🇸 PARPi in Patients With HRR-Negative mCRPC: Why Would These Therapies Work in the Absence of a Mutation? 🔸DNA proficient tumor cells tx w iPARP with hormonal agents, radioligands & IO (figures)

#GU23 ASCO Abs #726: Clinical characteristics, tumor genomic and transcriptomic profiles of pts with #mRCC who developed VTE: hormone metabolic, organic acid transport, extracellular matrix pathways associated with elevated risk of VTE. #meritaward tinyurl.com/ye2xf7mf

Thanks ASCO for the opportunity! 🇲🇽👩🏻‍⚕️ 💙 Best of journals in Medical Oncology for RCC #kidneycancer IKCC Kidney Cancer 🔸Triple therapy in mRCC 🔹TKI & IO cabo+nivo one of the highest responses in non-clear cell 🔸Pembro continues to have DFS. Atezolizumab & Ipi/Nivo no DFS or OS

Updated COSMIC 313 results presented by Tom Powles ASCO #GU23

Cabopoint prospectively explores cabo in ICI refactory disease. RR of 30% post ipi/nivo and 25% post VEGF/ICI therapy show sequencing these agents is of benifit. It strengthens the data for Cabo in this setting which joins axi and pazo with prospect data in this setting. #GU23

Very high yield overview of adjuvant IO in #RCC by Matthew Zibelman: ❓diff btwn PD1 or PDL1? KN564 pembro (only FDA approved) 🛑 no benefit in IMmotion010 (PDL1 atezo), CM-914 (ipi/nivo) and PROSPER (periop nivo) ➡️ What matters to clinicians/pts? OS, prioritize most at risk #GU23

Updates in non-clear-cell RCC by Dr. McGregor #GU23 🌀PAPMET: papillary RCC OS cabo>sunitinib ➡️MET: savolitinib trials ongoing ✳️HRLCC: Bev+erlotinib, trial adding atezo 🌀IO/VEGF generally > IO alone ➡️ many advances, histology directed therapy ultimate goal, trials ongoing

Don't leave #GU23 without visiting this interesting poster authored by our Editorial Board Member Fernando Sabino, MD, PhD and this incredible team! ⬇️ 🇧🇷

We need to keep encouraging #HPVvaccination to continue to see trends in the prevention of HPV-associated cancers: cervical, oropharyngeal, anorectal & penile cancers #GU23 by Maarten Albersen: 🌀routine 💉@ 9-12yo 🌀catch-up 💉@ 13-26yo 🌀shared-decision 💉 @ 27-45yo

#GU23 in this observational study of 1st line tx (IO v TKI) in #mRCC, interesting to see from a #radonc perspective 📈SRS 📉WBRT SRS & resection associated with⬆️OS - likely better prognosis at baseline, but underscores importance of aggressive local tx in these pts OncoAlert

⚡️Does a PARP inhibitor in men w/tx naïve high-risk nmHSPC allow delay of ADT and onset of metastasis? ✅Dr. Sahu discusses his promising study and spoke highly of his mentors Benjamin L Maughan Neeraj Agarwal, MD, FASCO Dr. Kamal Kant Sahu ASCO #GU23 👇 vumedi.com/channel/asco-g…

⭐️BEST parts of ASCO #GU23 1️⃣Catching up with friends 2️⃣Learning new ideas 3️⃣FUN conversations 4️⃣Making new friends. Amit M Neeraj Agarwal, MD, FASCO Sumanta K. Pal, MD, FASCO Christine Parker Amanda Nizam, MD Petros Grivas Dimitra R. Bakaloudi MD, MS, MPA Albert Jang, MD Yousef Zakharia Rohit Jain, MD Vadim Koshkin MD Tanya Jindal

⚡️Tanya Jindal and I talk about her UNITE study w/Dr. Koshkin. ✅Favorite moments of ASCO #GU23 include talking to rising ⭐️s in GU about their research and the impact of their outstanding mentors. Vadim Koshkin MD Petros Grivas Pedro C Barata, MD MSc FACP Benjamin L Maughan OncoAlert

Just in #ASCODailyNews 👉SPOP mutation as predictive biomarker for Rx selection for ARSIs in mHSPC #prostatecancer & potential use in “de-escalation”. Excellent article by our star trainee Georges Gebrael 👇 & GU Cancer Research Program @HuntsmanCancer team Umang Swami, MD, MSCI, FASCO Nicolas Sayegh, MD Cc’ing: PCF Science UroToday.com